Axsome Therapeutics Financials - Benzinga

Axsome Therapeutics Inc

AXSMNASDAQ

Trade with Public

Trade with Public

$205.40

마지막 업데이트: Aug 24, 4:00 PM

개요 뉴스 실적 전망 이벤트 목표가재무심리 지분 현황 비교 옵션 주식 보고서

Axsome Therapeutics Financials

Axsome Therapeutics (AXSM) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

Axsome Therapeutics Analysts Increase Their Forecasts Following Q2 Results

Axsome Therapeutics (NASDAQ:AXSM) reported Q2 losses of 99 cents per share and sales of $218.4 million, missing analyst estimates. Analysts have mixed price targets for the stock.

Avi Kapoor

PRO
Axsome Therapeutics Q2 EPS $(0.99) Misses $(0.83) Estimate, Sales $218.400M Miss $221.230M Estimate

Axsome Therapeutics (NASDAQ:AXSM) reported quarterly losses of $(0.99) per share which missed the analyst consensus estimate of $(0.83) by 19.28 percent. This is a 110.64 percent decrease over losses of $(0.47) per

Benzinga Newsdesk

Strong Drug Sales Lift Axsome Revenue, But Profit Miss Drags Stock

Axsome (AXSM) Q1: Revenue beats, but wider loss and rising expenses weigh on shares. Get the key data on Sunosi and Auvelity sales.

Vandana Singh

Earnings Scheduled For May 4, 2026

Benzinga Insights

PRO
Axsome Therapeutics Q1 EPS $(1.26) Misses $(0.90) Estimate, Sales $191.203M Beat $189.193M Estimate

Axsome Therapeutics (NASDAQ:AXSM) reported quarterly losses of $(1.26) per share which missed the analyst consensus estimate of $(0.90) by 40 percent. This is a 85.29 percent decrease over losses of $(0.68) per share

Benzinga Newsdesk

PRO
Axsome Therapeutics Q4 EPS $(0.56) Beats $(0.68) Estimate, Sales $195.999M Beat $193.107M Estimate

Axsome Therapeutics (NASDAQ:AXSM) reported quarterly losses of $(0.56) per share which beat the analyst consensus estimate of $(0.68) by 17.4 percent. This is a 30 percent increase over losses of $(0.80) per share from

Benzinga Newsdesk

© 2026 Benzinga | All Rights Reserved